Refractory Multiple Myeloma Pipeline Expands as 75+ Pharma Companies Advance 80+ Novel Blood Cancer Therapies, Finds DelveInsight | Bristol Myers Squibb, Novartis, AbbVie, I-Mab Biopharma, Cellectar Biosciences

DelveInsight's "Refractory Multiple Myeloma – Pipeline Insight, 2026" report provides comprehensive insights about 75+ companies developing several pipeline drugs in the Refractory Multiple Myeloma pipeline landscape. It covers the Refractory Multiple Myeloma pipeline drug profiles, including clinical and nonclinical stage products, along with therapeutics assessment by product type, stage, route of administration, and molecule type, and further highlights inactive pipeline products in this space.

Explore the latest breakthroughs in the Refractory Multiple Myeloma treatment landscape. Learn more about the evolving Refractory Multiple Myeloma pipeline today @ https://www.delveinsight.com/sample-request/refractory-multiple-myeloma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr

Key Takeaways from the Refractory Multiple Myeloma Pipeline Report

• In April 2026, findings from the Phase 3 IsKia trial confirmed that the Isa-KRd quadruplet regimen significantly increased MRD negativity rates across every treatment phase compared to standard triplets in multiple myeloma.
• In September 2025, clinical focus intensified on managing high infection risks associated with immune-based therapies, particularly BCMA-targeted CAR T-cell therapies and bispecific antibodies (BsAbs).
• In December 2020, Phase 1 results for the BCMA CD3-targeted bispecific antibody elranatamab demonstrated an 83% clinical response rate at study doses.
• In August 2020, the FDA granted regulatory approval to belantamab mafodotin-blmf (Blenrep) for relapsed/refractory multiple myeloma patients who received four prior therapies.
• Refractory Multiple Myeloma occurs when the disease, originating in plasma cells, becomes resistant to treatment or fails to respond to initial therapies, often leading to a poorer outlook.
• DelveInsight's Refractory Multiple Myeloma Pipeline Insight report depicts a robust clinical development space with over 75 active players advancing 80+ pipeline therapies across stages from discovery to Phase III.
• Bristol Myers Squibb is investigating novel CELMoD agents, such as mezigdomide and iberdomide, designed to improve upon established immunomodulatory drug efficacy with manageable tolerability.
• Felzartamab, a human monoclonal antibody targeting CD38, is currently in Phase III clinical trials as a foundational therapeutic candidate.
• RAPA-201, an autologous cell therapy, is being evaluated in Phase II for its gene transference capabilities in treating refractory cases.
• Leading companies in this space include Bristol Myers Squibb, Novartis, AbbVie, I-Mab Biopharma, RAPA Therapeutics, Cellectar Biosciences, Takeda, and others.

Download for updates and the latest revolution in Refractory Multiple Myeloma care @ https://www.delveinsight.com/sample-request/refractory-multiple-myeloma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr

Refractory Multiple Myeloma Emerging Drugs Profile

• Felzartamab: I-Mab Biopharma
Felzartamab is an investigational human monoclonal antibody directed against the CD38 receptor on the surface of multiple myeloma cells. Utilizing innovative technology derived from MorphoSys' HuCAL, it is designed to trigger targeted cell death. Currently, Felzartamab is in Phase III clinical trial evaluation, representing a significant advancement in the anti-CD38 therapeutic class for patients who have failed prior lines of therapy.

• RAPA-201: RAPA Therapeutics
RAPA-201 is a novel autologous cell therapy under development for the treatment of blood cancers. The therapy utilizes advanced gene transference techniques to reprogram a patient's own immune cells to combat refractory disease. Currently, RAPA-201 is in Phase II clinical evaluation, where its efficacy and safety are being rigorously tested in patients with multiple myeloma who have become resistant to standard proteasome inhibitors and immunomodulatory drugs.

• PHE885: Novartis
PHE885 is an investigational BCMA-targeted chimeric antigen receptor (CAR) T-cell therapy infusion. It involves genetically changing a patient's T cells to specifically target and attack myeloma cells expressing the B-cell maturation antigen. Currently, PHE885 is in Phase II testing, focusing on achieving deep clinical responses while carefully monitoring for dose-limiting toxicities and adverse events such as cytokine release syndrome.

For more information on the Refractory Multiple Myeloma Emerging Drugs Profile, download DelveInsight's comprehensive Refractory Multiple Myeloma Pipeline Insight report @ https://www.delveinsight.com/sample-request/refractory-multiple-myeloma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr

The Refractory Multiple Myeloma Pipeline Report Provides

• Detailed insights about companies developing therapies for Refractory Multiple Myeloma, with aggregate therapies developed by each company.
• Different therapeutic candidates, segmented into early-stage, mid-stage, and late-stage of development for Refractory Multiple Myeloma treatment.
• Refractory Multiple Myeloma companies that are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Refractory Multiple Myeloma drugs under development based on stage of development, route of administration, target receptor, monotherapy or combination therapy, mechanism of action, and molecular type.
• Detailed analysis of collaborations, licensing agreements, and financing details for future advancement of the market.

Learn more about Refractory Multiple Myeloma drug opportunities in our comprehensive Refractory Multiple Myeloma pipeline report @ https://www.delveinsight.com/sample-request/refractory-multiple-myeloma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr

Refractory Multiple Myeloma Companies and Competitive Landscape

There are 75+ key companies, including Bristol Myers Squibb, Novartis, AbbVie, I-Mab Biopharma, RAPA Therapeutics, Cellectar Biosciences, Takeda, and Sanofi, developing therapies for Refractory Multiple Myeloma, with candidates like Felzartamab reaching the advanced Phase III stage.

DelveInsight's Refractory Multiple Myeloma pipeline report provides the therapeutic assessment of the pipeline drugs by Route of Administration. Products have been categorized under various ROAs such as:

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Refractory Multiple Myeloma products have been categorized under various Molecule types such as:

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Discover the latest advancements in Refractory Multiple Myeloma treatment by visiting our website. Stay informed @ https://www.delveinsight.com/sample-request/refractory-multiple-myeloma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr

Scope of the Refractory Multiple Myeloma Pipeline Report

• Coverage: Global
• Refractory Multiple Myeloma Companies: Bristol Myers Squibb, Novartis, AbbVie, I-Mab Biopharma, RAPA Therapeutics, Cellectar Biosciences, Takeda, Sanofi, and others.
• Refractory Multiple Myeloma Therapies: Felzartamab, RAPA-201, PHE885, ABBV-453, mezigdomide, elranatamab, and others.
• Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination.
• Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III.

Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: info@delveinsight.com
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe, helping them stay ahead of the growth curve.

This release was published on openPR.